Evaluating the efficacy of compound MP-001 in survival,
motor function and muscular markers in SOD1G93A mice
We also investigated on SOD1G93A mice the therapeutic
potential of the compound MP-001 (Fig. 5A), characterized by limited or
negligible CNS availability (Fig. 1), thereby confining its mechanism of
action to peripheral tissues. The body weight of all animals was
monitored weekly from 8 weeks of age until 22 weeks. We observed reduced
weight loss in the treated animals, with significant differences at the
13th and 15th weeks of age (Fig. 5B). However, as depicted in the
survival analysis, MP-001 treatment did not significantly extend the
survival of SOD1G93A mice (Fig. 5C). Regarding the
results obtained in the motor tests, no discernible improvement was
observed in the SOD1G93A mice treated with MP-001
(Figure 5D,E).